Clinical Trials Logo

Filter by:
NCT ID: NCT04819490 Completed - Clinical trials for X-Linked Hypophosphataemia

A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLH

Start date: April 1, 2021
Phase:
Study type: Observational [Patient Registry]

This study aims to provide Health-related Quality of Life (HRQoL) data from children and adolescents with growing skeletons in the United Kingdom (UK), including those treated with burosumab or alternative XLH treatment, as part of an updated submission to the SMC in early 2023. This study will utilise data from a subset of UK sites already within the XLH Registry (including participating Scottish sites) and collect additional HRQoL data within these sites (that are otherwise not included in the wider XLH Registry protocol). The HRQoL data will enable the calculation of HRQoL to derive the HRQoL utility estimates in children and adolescents with growing skeletons for the RSS health states, hence addressing an area of uncertainty.

NCT ID: NCT04819945 Completed - Clinical trials for Hemorrhage, Surgical

Clinical Safety and Performance of GATT-Patch in Open Liver Surgery

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the clinical safety and performance of GATT-Patch for management of haemorrhage during elective open liver surgery.

NCT ID: NCT04820426 Completed - Clinical trials for Rheumatoid Arthritis

Evaluation of the Effect of Neuropathic Pain on Quality of Life in Rheumatoid Arthritis Patients

Start date: April 1, 2021
Phase:
Study type: Observational

Rheumatoid arthritis is a chronic inflammatory disease that mainly affects the joint synovium. Rheumatoid arthritis patients define pain as their major symptom and the most important reason for applying to a healthcare institution. Approximately 70% of rheumatoid arthritis patients state that improvement in their pain compared to other symptoms of the disease is their priority. Pain in rheumatoid arthritis patients is also important as the disease affects approximately 0.5-1% of patients worldwide. Although pain in rheumatoid arthritis patients can be persistent or intermittent, localized or widespread, it has often been associated with fatigue and psychosocial stress. Although nociceptive pain,defined as 'gnawing' or 'aching', is frequently observed in rheumatoid arthritis patients, typical neuropathic pain,such as 'burning' or 'itching', can be observed in some RA patients. It is thought that neuropathic pain may occur as a result of lesions or disease affecting the somatosensorial nervous system. Neuropathic pain can occur with little or no stimulus, and its symptoms are abnormal sensations such as hyperalgesia and allodynia. The diagnosis and treatment of neuropathic pain in rheumatoid arthritis patients is important because neuropathic pain does not decrease with traditional disease-modifying anti-inflammatory drugs used in rheumatoid arthritis and causes a decrease in quality of life. In order to distinguish neuropathic pain from chronic pain, methods based on defining the quality of pain are often used. Some of these methods are; The McGill Pain Questionnaire, PainDETECT, RAPS (Rheumatoid Arthritis Pain Scale), VAS (visual analog scale), AIMS (Arthritis Impact Scale), EQ-5D (European Quality of Life Assessment and Pain Assessment Questionnaire). The diagnosis and treatment of neuropathic pain in rheumatoid arthritis patients is important because neuropathic pain does not decrease with traditional disease-modifying anti-inflammatory drugs used in rheumatoid arthritis and causes a decrease in quality of life.

NCT ID: NCT04821986 Completed - SARS-CoV Infection Clinical Trials

Oral Manifestation in Patients With SARS-CoV2 Infection.

Start date: April 1, 2021
Phase:
Study type: Observational

The oral cavity is particularly susceptible to viral infection with several viruses such as herpes simplex virus, cytomegalovirus and Zika virus because of its structures, especially salivary glands and soft tissues Moreover, oral mucosa can be affected by secondary pathological process of a bacterial or fungal nature due to viral immunosuppression. The oral cavity could be considered a "biological barometer" of both viral infection and viral immunosuppression advancement .

NCT ID: NCT04822389 Completed - Lymphoma Clinical Trials

Telerehabilitation and Lymphoma Patients

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

This study aims to examine the feasibility and effect of a home-based short-term telerehabilitation exercise intervention using heart rate monitor and internet platform in patients with lymphoma.

NCT ID: NCT04822519 Completed - Gall Stone Clinical Trials

RISK FACTORS OF GALL BLADDER STONE

Start date: April 1, 2021
Phase:
Study type: Observational

Gallbladder disease is a significant health burden in the developed world and its prevalence has risen by more than 20% in the past three decades In the United States, 20-25 million individuals are affected by gallbladder disease, resulting in an average annual treatment cost of $6.2 billion Obesity, diet, rapid weight loss, metabolic syndrome, and conditions such as cirrhosis, Crohn's disease, irritable bowel syndrome, and gallbladder stasis increase the risk of gallstone formation Surgical removal of the gallbladder, cholecystectomy, is the most recommended treatment for gallbladder disease; however, the procedure increases the risk of non-alcoholic fatty liver disease, cirrhosis and metabolic effects

NCT ID: NCT04822844 Completed - Clinical trials for Postoperative Nausea and Vomiting (PONV)

Implementing a Nurse-Driven Aromatherapy Protocol to Decrease the Effect of Postoperative Nausea and Vomiting

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

This is a quality improvement project that aims to assess the effect of nurse-driven administration of essential oil aromatherapy on postoperative nausea and vomiting (PONV) in patients while in the post-anesthesia care unit (PACU) after general anesthesia.

NCT ID: NCT04823702 Completed - Clinical trials for Impaired Hepatic Function

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

Start date: April 1, 2021
Phase: Phase 1
Study type: Interventional

This is an evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Hepatic Function

NCT ID: NCT04823884 Completed - Hallux Valgus Clinical Trials

Short-term Results After Minimally Invasive Chevron Osteotomy for Hallux Valgus Correction

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

By means of clinical satisfaction and clinical scores comparison of an open to a minimally invasive distal chevron osteotomy for correction of a hallux valgus deformity is performed.

NCT ID: NCT04825015 Completed - Clinical trials for Liver Transplant; Complications

Hemodynamic Monitoring in Liver Transplant With VEnaRt Cardiac Output Versus Swan-Ganz Catheter (VERO Study)

VERO
Start date: April 1, 2021
Phase:
Study type: Observational

The Swan-Ganz catheter is the gold standard to measure cardiac output during liver transplantation surgery. This is an invasive hemodynamic monitoring system. The VenArt Cardiac Output (Mespere LifeSciences, Waterloo, Canada) is a new, innovative and non-invasive device that permits hemodynamic monitoring. With a software based on Fick's principle it is able to calculate cardiac output, cardiac index and continuous cardiac output. The hypothesis of this study is to investigate the precision and accuracy of this method versus the standard of care during liver transplantation.